154 related articles for article (PubMed ID: 27699266)
1. Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.
Abikhair M; Mitsui H; Yanofsky V; Roudiani N; Ovits C; Bryan T; Oberyszyn TM; Tober KL; Gonzalez J; Krueger JG; Felsen D; Carucci JA
JCI Insight; 2016 Jun; 1(8):e86434. PubMed ID: 27699266
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.
Abikhair Burgo M; Roudiani N; Chen J; Santana AL; Doudican N; Proby C; Felsen D; Carucci JA
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185657
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma.
Santana AL; Felsen D; Carucci JA
Dermatol Clin; 2017 Jan; 35(1):73-84. PubMed ID: 27890239
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients.
Kosmidis M; Dziunycz P; Suárez-Fariñas M; Mühleisen B; Schärer L; Läuchli S; Hafner J; French LE; Schmidt-Weber C; Carucci JA; Hofbauer GF
J Immunother; 2010 Jun; 33(5):538-46. PubMed ID: 20463594
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice.
Rafferty P; Egenolf D; Brosnan K; Makropoulos D; Jordan J; Meshaw K; Walker M; Volk A; Bugelski PJ
J Immunotoxicol; 2012; 9(1):43-55. PubMed ID: 22299716
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway.
Walsh SB; Xu J; Xu H; Kurundkar AR; Maheshwari A; Grizzle WE; Timares L; Huang CC; Kopelovich L; Elmets CA; Athar M
Mol Carcinog; 2011 Jul; 50(7):516-27. PubMed ID: 21308804
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine a in carcinogenesis.
Tiu J; Li H; Rassekh C; van der Sloot P; Kovach R; Zhang P
Laryngoscope; 2006 May; 116(5):762-9. PubMed ID: 16652084
[TBL] [Abstract][Full Text] [Related]
8. Altered density, composition and microanatomical distribution of infiltrating immune cells in cutaneous squamous cell carcinoma of organ transplant recipients.
Strobel SB; Safferling K; Lahrmann B; Hoffmann JH; Enk AH; Hadaschik EN; Grabe N; Lonsdorf AS
Br J Dermatol; 2018 Aug; 179(2):405-412. PubMed ID: 29479687
[TBL] [Abstract][Full Text] [Related]
9. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate.
Mühleisen B; Petrov I; Gächter T; Kurrer M; Schärer L; Dummer R; French LE; Hofbauer GF
Histopathology; 2009 Jul; 55(1):67-76. PubMed ID: 19614769
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.
Arumugam A; Walsh SB; Xu J; Afaq F; Elmets CA; Athar M
Biochem Biophys Res Commun; 2012 Aug; 425(2):177-81. PubMed ID: 22820192
[TBL] [Abstract][Full Text] [Related]
11. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A.
Dziunycz PJ; Lefort K; Wu X; Freiberger SN; Neu J; Djerbi N; Iotzowa-Weiss G; French LE; Dotto GP; Hofbauer GFL
J Invest Dermatol; 2014 Jul; 134(7):1998-2004. PubMed ID: 24509533
[TBL] [Abstract][Full Text] [Related]
12. Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients.
Mühleisen B; Petrov I; Frigerio S; Dziunycz P; French LE; Hofbauer GF
Arch Dermatol; 2012 Jun; 148(6):697-703. PubMed ID: 22508773
[TBL] [Abstract][Full Text] [Related]
13. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.
Dworkin AM; Tober KL; Duncan FJ; Yu L; VanBuskirk AM; Oberyszyn TM; Toland AE
Genes Chromosomes Cancer; 2009 Jun; 48(6):490-501. PubMed ID: 19296524
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A-treated dendritic cells may affect the outcome of organ transplantation by decreasing CD4+CD25+ regulatory T cell proliferation.
Pino-Lagos K; Michea P; Sauma D; Alba A; Morales J; Bono MR; Fierro A; Rosemblatt M
Biol Res; 2010; 43(3):333-7. PubMed ID: 21249305
[TBL] [Abstract][Full Text] [Related]
16. Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines.
Chen Z; Colon I; Ortiz N; Callister M; Dong G; Pegram MY; Arosarena O; Strome S; Nicholson JC; Van Waes C
Cancer Res; 1998 Aug; 58(16):3668-76. PubMed ID: 9721877
[TBL] [Abstract][Full Text] [Related]
17. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).
Khariwala SS; Kjaergaard J; Lorenz R; Van Lente F; Shu S; Strome M
Laryngoscope; 2006 May; 116(5):814-20. PubMed ID: 16652094
[TBL] [Abstract][Full Text] [Related]
18. A short course of cyclosporine immunosuppression inhibits rejection but not tolerance of rat liver allografts.
Huang WH; Yan Y; De Boer B; Bishop GA; House AK
Transplantation; 2003 Feb; 75(3):368-74. PubMed ID: 12589161
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
Li Z; Zhang D; Gao J; Li WX; Zhu JY
Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
[TBL] [Abstract][Full Text] [Related]
20. 1alpha,25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants.
Redaelli CA; Wagner M; Günter-Duwe D; Tian YH; Stahel PF; Mazzucchelli L; Schmid RA; Schilling MK
Kidney Int; 2002 Jan; 61(1):288-96. PubMed ID: 11786111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
